Breaking News Instant updates and real-time market news.

VRAY

ViewRay

$3.34

0.02 (0.60%)

, MDT

Medtronic

$110.93

-0.48 (-0.43%)

16:05
12/02/19
12/02
16:05
12/02/19
16:05

ViewRay announces collaborations with Medtronic, Elekta

ViewRay (VRAY) announced that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (EKTA-B) to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement. Additionally, ViewRay has signed a non-binding memorandum of understanding with Medtronic (MDT) to enter into a clinical collaboration in an area of mutual interest that includes exploring the clinical benefits of the MRIdian MR-guided radiation therapy system. In connection with the collaboration, Medtronic has committed to invest in a minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement. ViewRay's largest shareholder, Fosun International Limited, has also committed capital up to an amount that would enable it to maintain its current beneficial ownership percentage in ViewRay, subject to the terms and conditions set forth in a commitment agreement. The investments from Elekta and Medtronic are conditioned upon the consummation of an equity capital raise of at least $75M. The key objective of the collaboration with Elekta is to advance MR-linac technology and its application as the radiation therapy with superior precision, medical outcomes, and operational cost efficiency. The companies intend to facilitate clinical studies exploring the impact of MR-guided therapy in oncology and work jointly to expand the potential role of MR-guided therapy into other areas that could benefit from the technology. The companies are also exploring initiatives such as the formation of a cooperative group and working on healthcare policy. The collaboration is subject to the execution of definitive documentation. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay. Elekta's investment in ViewRay is subject to the terms and conditions set forth in a commitment agreement, including the condition of consummation of an equity capital raise of at least $75M. In addition, Elekta's investment in ViewRay is subject to an aggregate cap of $36M.

VRAY

ViewRay

$3.34

0.02 (0.60%)

MDT

Medtronic

$110.93

-0.48 (-0.43%)

  • 03

    Dec

VRAY ViewRay
$3.34

0.02 (0.60%)

09/16/19
PIPR
09/16/19
NO CHANGE
Target $6
PIPR
Overweight
ViewRay recent orders 'incremental positives,' says Piper Jaffray
ViewRay this morning announced that Penn State Health has entered a master agreement to purchase up to four MRIdian systems with the immediate order of one system and the ability to order an additional three systems in the future, Piper Jaffray analyst Matt O'Brien tells investors in a research note. This news follows an announcement last Thursday of an MRIdian order from Stanford Health Care, adds the analyst. He views these orders as "incremental positives" and further evidence of the "unique capabilities" of the MRIdian system. O'Brien reiterates an Overweight rating on ViewRay with a $6 price target.
10/15/19
PIPR
10/15/19
NO CHANGE
Target $6
PIPR
Overweight
ViewRay preannounced better than expected Q3, says Piper Jaffray
ViewRay this morning preannounced better than expected Q3 sales results after installing three systems compared to the Street estimate at two, Piper Jaffray analyst Matt O'Brien tells investors in a research note. Further, the eight MRIdian system orders in Q3, including three upgrades, were in-line with expectations and a "welcome sight" as investors had worried that hesitancy around the proposed reimbursement bundle would result in significant delays in purchasing decisions, adds the analyst. He views the results as "largely positive" and reiterates an Overweight rating on ViewRay shares with a $6 price target. O'Brien, who admits the company's cash burn was a little higher than he had modeled, sees a "compelling entry point" at current ViewRay share levels.
10/21/19
OPCO
10/21/19
INITIATION
Target $7
OPCO
Outperform
ViewRay initiated with an Outperform at Oppenheimer
Oppenheimer analyst Suraj Kalia initiated coverage of ViewRay with an Outperform rating and $7 price target.
10/21/19
OPCO
10/21/19
INITIATION
Target $7
OPCO
Outperform
Oppenheimer starts ViewRay with Outperform rating, $7 price target
Oppenheimer analyst Suraj Kalia initiated coverage of ViewRay with an Outperform rating and $7 price target. The promise of ViewRay's technology is in superior outcomes and lower toxicity, says Kalia, who estimates that 20%-30% of all medical linear accelerators placed within ten years will have magnetic resonance-guided capabilities. "We are in the first innings of a highly disruptive technology adoption curve," Kalia tells investors in a research note.
MDT Medtronic
$110.93

-0.48 (-0.43%)

11/20/19
OPCO
11/20/19
NO CHANGE
Target $123
OPCO
Outperform
Medtronic price target raised to $123 from $118 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Medtronic to $123 from $118 following the company's Q2 results, saying free cash flow generation remains "solid" and believes cash use is a potential upside driver through tuck-in M&A and/or stock buybacks.
11/20/19
RBCM
11/20/19
NO CHANGE
Target $122
RBCM
Outperform
Medtronic price target raised to $122 from $118 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Medtronic to $122 and kept his Outperform rating after its "solid" Q2 results and raised FY20 earnings guidance. The analyst notes that the company's Restorative Therapies Group segment constant-currency revenue growth of 6.8% topped the management's guidance by 220bps and its Minimally Invasive Therapies Group segment growth of 6.1% exceeded forecasts by 35bps. Henry further boosts his FY20 and FY21 EPS views by 3c and 4c to $5.60 and $6.04 respectively while noting that his FY20 guidance assumes 40bps of operating margin expansion.
11/20/19
DBAB
11/20/19
NO CHANGE
Target $123
DBAB
Buy
Medtronic price target raised to $123 from $118 at Deutsche Bank
Deutsche Bank analyst Pito Chickering raised Medtronic's price target to $123 from $118 saying the company's Q2 "brought no major surprises." The analyst expects sales growth acceleration in the second half of the fiscal year and 2021 and keeps a Buy rating on the shares.
11/25/19
ARGS
11/25/19
NO CHANGE
Target $135
ARGS
Buy
Medtronic price target raised to $135 from $120 at Argus
Argus analyst David Toung raised his price target on Medtronic to $135 and kept his Buy rating after its Q2 earnings beat that was driven by growth upside in Restorative Therapies Group and the Minimally Invasive Therapies Group businesses. The analyst also cites the company's "solid performance in emerging markets" and the strong sales of its diabetes products overseas, raising his FY20 and FY21 EPS views by 3c and 2c to $5.63 and $6.12 respectively.

TODAY'S FREE FLY STORIES

01:45
12/10/19
12/10
01:45
12/10/19
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

21:55
12/09/19
12/09
21:55
12/09/19
21:55
General news
Treasury Market Summary »

Treasury Market Summary:…

AUPH

Aurinia Pharmaceuticals

$15.76

0.31 (2.01%)

21:03
12/09/19
12/09
21:03
12/09/19
21:03
Syndicate
Aurinia Pharmaceuticals 11.1M share Secondary priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

20:08
12/09/19
12/09
20:08
12/09/19
20:08
Downgrade
Gardner Denver rating change at BTIG »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

19:56
12/09/19
12/09
19:56
12/09/19
19:56
Downgrade
Gardner Denver rating change at BTIG »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTCWY

Deutsche Wohnen

$0.00

(0.00%)

19:50
12/09/19
12/09
19:50
12/09/19
19:50
Downgrade
Deutsche Wohnen rating change at Goldman Sachs »

Deutsche Wohnen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEGXF

Segro

$0.00

(0.00%)

19:49
12/09/19
12/09
19:49
12/09/19
19:49
Downgrade
Segro rating change at Goldman Sachs »

Segro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BORR

Borr Drilling

$6.60

0.46 (7.49%)

19:30
12/09/19
12/09
19:30
12/09/19
19:30
Initiation
Borr Drilling initiated at Goldman Sachs »

Borr Drilling initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSG

Inseego

$6.89

-0.05 (-0.72%)

19:26
12/09/19
12/09
19:26
12/09/19
19:26
Syndicate
Breaking Syndicate news story on Inseego »

Inseego files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$30.44

16.04 (111.39%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Forty Seven to hold an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ARQL

ArQule

$19.71

10.035 (103.77%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
ArQule »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

XNCR

Xencor

$41.41

0.39 (0.95%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Xencor to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ABR

Arbor Realty

$14.78

(0.00%)

19:20
12/09/19
12/09
19:20
12/09/19
19:20
Syndicate
Arbor Realty 6.5M share Spot Secondary priced at $14.14 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

STRM

Streamline Health

$1.25

-0.04 (-3.10%)

18:59
12/09/19
12/09
18:59
12/09/19
18:59
Hot Stocks
Streamline Health delaying Q3 results to resolve amortization charge »

Streamline Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

, INTC

Intel

$56.52

-0.28 (-0.49%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Periodicals
McAfee weighs combination with NortonLifeLock, WSJ reports »

NortonLifeLock (NLOK) has…

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

INTC

Intel

$56.52

-0.28 (-0.49%)

AVGO

Broadcom

$314.49

-1.68 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 19

    Dec

  • 23

    Jan

TGTX

TG Therapeutics

$9.28

2.17 (30.52%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Conference/Events
TG Therapeutics to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

NTNX

Nutanix

$33.87

-0.725 (-2.10%)

18:41
12/09/19
12/09
18:41
12/09/19
18:41
Hot Stocks
Nutanix CEO: We are transitioning to a subscription-based model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

  • 16

    Dec

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

, MDB

MongoDB

$131.03

-0.19 (-0.14%)

18:33
12/09/19
12/09
18:33
12/09/19
18:33
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Stitch…

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

MDB

MongoDB

$131.03

-0.19 (-0.14%)

PHR

Phreesia

$29.01

-0.09 (-0.31%)

CDMO

Avid Bioservices

$5.85

0.05 (0.86%)

MTN

Vail Resorts

$231.30

-1.43 (-0.61%)

TOL

Toll Brothers

$41.40

0.515 (1.26%)

EQ

Equillium

$4.00

-0.03 (-0.74%)

SUPN

Supernus

$22.69

-0.145 (-0.63%)

A

Agilent

$81.68

-0.545 (-0.66%)

HEPA

Hepion Pharmaceuticals

$5.61

0.4 (7.68%)

ROAD

Construction Partners

$20.56

0.66 (3.32%)

CASY

Casey's General Stores

$175.33

-0.47 (-0.27%)

CHWY

Chewy

$24.17

-0.76 (-3.05%)

LVGO

Livongo Health

$27.40

-0.6 (-2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

  • 18

    Dec

  • 19

    Dec

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

, BMY

Bristol-Myers

$61.32

1.38 (2.30%)

18:24
12/09/19
12/09
18:24
12/09/19
18:24
Hot Stocks
Bluebird Bio, Bristol-Myers present update on Phase 1 study of bb21217 »

Bluebird bio (BLUE) and…

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

BMY

Bristol-Myers

$61.32

1.38 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

BA

Boeing

$351.25

-2.74 (-0.77%)

18:22
12/09/19
12/09
18:22
12/09/19
18:22
Periodicals
Former Boeing employee Pierson to testify at U.S. House hearing, Reuters says »

An ex-Boeing employee who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:21
12/09/19
12/09
18:21
12/09/19
18:21
Hot Stocks
Occidental Petroleum director buys 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:14
12/09/19
12/09
18:14
12/09/19
18:14
Hot Stocks
Occidental Petroleum director buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

EDIT

Editas Medicine

$30.34

-0.6 (-1.94%)

18:02
12/09/19
12/09
18:02
12/09/19
18:02
Hot Stocks
Editas Medicine announces in vivo proof-of-concept data for EDIT-301 »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

, CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

17:56
12/09/19
12/09
17:56
12/09/19
17:56
Hot Stocks
Mesabi Trust initiates arbitration against Northshore Mining, Cleveland-Cliffs »

The Trustees of Mesabi…

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFBC

First Financial Bancorp

$24.67

0.12 (0.49%)

17:51
12/09/19
12/09
17:51
12/09/19
17:51
Hot Stocks
First Financial Bancorp chairman Davis sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.